Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 21 Carcinoma, Renal Cell 18 HIV Infections 6 Acquired Immunodeficiency Syndrome 6 Sarcoma, Kaposi 5 Leukemia 5 Neoplasm Metastasis 4 Lymphoma 4 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4 Triple Negative Breast Neoplasms 3 Recurrence 3 Neoplasms 3 Kidney Neoplasms 3 Hematologic Neoplasms 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pancreatic Neoplasms 2 Mycosis Fungoides 2 Multiple Myeloma 2 Leukemia, Myeloid, Chronic-Phase 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Brain Neoplasms 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Tumor Virus Infections 1 Thrombocythemia, Essential 1 Solid Cancers 1

Interventions

Paclitaxel 326 Carboplatin 318 Bevacizumab 167 Gemcitabine 106 pembrolizumab 101 liposomal doxorubicin 100 Cyclophosphamide 96 Topotecan 93 Cisplatin 89 olaparib 86 niraparib 60 Docetaxel 56 Taxes 52 Doxorubicin 50 Drug Therapy 42 fludarabine 40 Filgrastim 39 Nivolumab 37 Etoposide 32 Specimen Handling 31 Magnetic Resonance Spectroscopy 29 Immunoglobulin G 27 Disulfides 27 Peripheral Blood Stem Cell Transplantation 26 Albumin-Bound Paclitaxel 25 durvalumab 24 aldesleukin 24 Hyperthermic Intraperitoneal Chemotherapy 24 Oxaliplatin 23 Biopsy 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Ovarian Neoplasms × Interferon alpha-2 × Clear all

NCT01639885 2014-01-07

CHIP

Leiden University Medical Center

Phase 1/2 Completed

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡